Karyopharm Therapeutics Inc
KPTI3.993USD
+0.063+1.60%
Horário de mercado （ET）Cotações atrasadas em 15 min
34.21MValor de mercado
PerdaP/L TTM
Mais detalhes de Karyopharm Therapeutics Inc Empresa
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Informações da empresa
Código da empresaKPTI
Nome da EmpresaKaryopharm Therapeutics Inc
Data de listagemNov 06, 2013
CEOMr. Richard A. Paulson
Número de funcionários279
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 06
Endereço85 Wells Avenue
CidadeNEWTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02459
Telefone16176580600
Sitehttps://karyopharm.com/
Código da empresaKPTI
Data de listagemNov 06, 2013
CEOMr. Richard A. Paulson
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
11.90K
-19.01%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.12K
-2.30%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
6.71K
-28.64%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brendan Strong
Mr. Brendan Strong
Senior Vice President - Investor Relations and Corporate Communications
Senior Vice President - Investor Relations and Corporate Communications
--
--
Dr. Mansoor Raza Mirza, M.D.
Dr. Mansoor Raza Mirza, M.D.
Independent Director and Clinical Consultant
Independent Director and Clinical Consultant
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
11.90K
-19.01%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.12K
-2.30%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
6.71K
-28.64%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
5.91%
J. Wood Capital Advisors LLC
5.30%
Adage Capital Management, L.P.
4.88%
Palo Alto Investors LP
3.75%
Eversept Partners, LP
2.98%
Other
77.19%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
5.91%
J. Wood Capital Advisors LLC
5.30%
Adage Capital Management, L.P.
4.88%
Palo Alto Investors LP
3.75%
Eversept Partners, LP
2.98%
Other
77.19%
Tipos de investidores
Investidores
Proporção
Hedge Fund
18.53%
Investment Advisor
13.01%
Corporation
5.30%
Research Firm
4.94%
Investment Advisor/Hedge Fund
4.53%
Venture Capital
1.80%
Individual Investor
1.11%
Pension Fund
0.05%
Other
50.74%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
284
4.26M
49.27%
-1.69M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
2023Q2
380
6.19M
81.48%
-2.04M
2023Q1
395
6.56M
86.55%
-1.62M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
510.29K
5.91%
-5.00
-0.00%
Mar 31, 2025
J. Wood Capital Advisors LLC
458.13K
5.3%
--
--
Apr 10, 2025
Adage Capital Management, L.P.
421.32K
4.88%
-1.00
-0.00%
Mar 31, 2025
Palo Alto Investors LP
324.03K
3.75%
-3.10K
-0.95%
Mar 31, 2025
Eversept Partners, LP
257.15K
2.98%
+117.90K
+84.67%
Mar 31, 2025
Citadel Advisors LLC
206.91K
2.39%
-2.00
-0.00%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
188.02K
2.18%
-1.00K
-0.53%
Mar 31, 2025
Catalio Capital Management, LP
155.62K
1.8%
-3.00
-0.00%
Mar 31, 2025
J.P. Morgan Securities LLC
147.42K
1.71%
+129.01K
+700.61%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
139.65K
1.62%
+139.65K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
iShares Morningstar Small-Cap Value ETF
0%
iShares Russell 3000 ETF
0%
Avantis US Equity ETF
0%
iShares Russell 2000 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
ProShares Hedge Replication ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proporção0%
iShares Morningstar Small-Cap Value ETF
Proporção0%
iShares Russell 3000 ETF
Proporção0%
Avantis US Equity ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Fidelity Enhanced Small Cap ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
iShares Genomics Immunology and Healthcare ETF
Proporção0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Feb 24, 2025
Merger
15<1
Feb 24, 2025
Merger
15<1
Feb 24, 2025
Merger
15<1
Feb 24, 2025
Merger
15<1
Data
Tipo
Proporção
Feb 24, 2025
Merger
15<1
Feb 24, 2025
Merger
15<1
Feb 24, 2025
Merger
15<1
Feb 24, 2025
Merger
15<1
